Grail (GRAL) is making its Galleri multicancer early detection test directly available to physicians in the US through its collaboration with Quest Diagnostics (DGX), the companies said Wednesday.
The companies said the test can now be ordered from Grail through Quest's connectivity system, helping streamline the process of ordering for physicians.
The integration of Grail's test into Quest's connectivity system will also increase availability by making the test accessible to patients at any Quest patient access point, the companies said.
Financial details of the collaboration weren't provided.
Price: 33.01, Change: -0.14, Percent Change: -0.42
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。